

April 27th, 2026

Acuitas Therapeutics Announces Four Scientific Presentations at the 2026 ASGCT Annual Meeting

Vancouver, B.C. – Acuitas Therapeutics, the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, today announced it will present new research at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The presentations will showcase Acuitas' latest advancements in the biology and mechanisms of LNP delivery, ranging from raw material quality control to cell-specific targeting.

The ASGCT Annual Meeting will be held from May 11 – 15, 2026, in Boston. Acuitas' researchers will share insights into how the chemical properties of lipids and the biological responses of the host environment can be optimized to create more potent, safer, and highly targeted genetic medicines.

“Acuitas is dedicated to advancing LNP technology through robust scientific validation and expanding its role in next-generation vaccines and therapeutics,” said Acuitas Chief Scientific Officer Ying Tam. “Our research at ASGCT reflects our belief that the most transformative RNA-based medicines are realized when we understand the complex biology and mechanisms of LNP delivery, facilitating our work alongside the global scientific community to accelerate life-changing treatments.”

Presentation Details:

- **Oral Presentation:** Ionizable lipid impurities drive RNA-lipid adduct formation in LNPs, impacting in vivo expression
 - **Presenter:** Razvan Cojocaru
 - **Session Title:** Lipid Chemistry, Delivery Mechanisms, and Manufacturing
 - **Session Date and Time:** May 15th, 2026, 8:45am – 9:00am
 - **Session Location:** MCEC Room 210 ABC (Level 2)
- **Poster Presentation:** Enhanced delivery and expression of mRNA to T-cells using CD8-targeted lipid nanoparticles with Athebody® Designed Ankyrin Repeat Proteins
 - **Presenter:** Grayson Wong

- **Session Title:** Wednesday Poster Reception
- **Session Date and Time:** May 13th, 2026, 5:00pm – 6:30pm
- **Session Location:** MCEC Exhibit and Poster Hall (Halls B2-C, Exhibit Level)
- **Poster Presentation:** Human whole blood assay investigations of lipid nanoparticle mRNA immune stimulation and mitigation
 - **Presenter:** Melissa Dennis
 - **Session Title:** Wednesday Poster Reception
 - **Session Date and Time:** May 13th, 2026, 5:00pm – 6:30pm
 - **Session Location:** MCEC Exhibit and Poster Hall (Halls B2-C, Exhibit Level)
- **Poster Presentation:** Alterations in NHP liver gene expression profiles following intravenous infusion of mRNA-LNP
 - **Presenter:** Hilda Au
 - **Session Title:** Wednesday Poster Reception
 - **Session Date and Time:** May 13th, 2026, 5:00pm – 6:30pm
 - **Session Location:** MCEC Exhibit and Poster Hall (Halls B2-C, Exhibit Level)

More information about the conferences can be found on the [ASGCT Annual Meeting website](#).

About Acuitas Therapeutics

Acuitas Therapeutics Inc., the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, is a Vancouver-based company collaborating with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases.

Acuitas' clinically validated LNP technology has had a profound global impact — most notably enabling the Pfizer-BioNTech COVID-19 vaccine, **COMIRNATY®**, which has protected billions of people in more than 180 countries. Its technology also enables **ONPATTRO®** by Alnylam Pharmaceuticals, the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis. More recently, Acuitas' LNP technology has delivered other



groundbreaking firsts: the **first in-human proof of concept** for genome base editing and the **first personalized CRISPR therapy**.

Today, Acuitas is advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic and *in vivo* CAR T-cell therapies, epigenetic medicines to modulate gene expression without altering DNA, and multivalent vaccines for infectious diseases — such as malaria, HIV/AIDS, and tuberculosis — as well as oncology vaccines, including personalized cancer vaccines.

For more information, visit www.acuitastx.com.

-END-

Media Contact:

Jakub Cikowski

HDMZ

acuitas.pr@hdmz.com